Ming-Wei Lee

Prof. Ming-Wei Lee


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Carbohydrate Polymers
Verified
Journal Article
Closed access
MLMing-Wei Lee
Ming-Wei Lee
HTHui-Fang Tsai
Hui-Fang Tsai
SWShu-Min Wen
Shu-Min Wen
CHChia-Hui Huang
Chia-Hui Huang

1 January 2018 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
Wan-Chi TsaiWan-Chi Tsai
Wan-Chi Tsai
HTHuifang Tsai
Huifang Tsai
YWYinuan Wong
Yinuan Wong
JHJuiyen Hong
Juiyen Hong
SCShwujen Chang
Shwujen Chang
MLMing-Wei Lee
Ming-Wei Lee

15 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MHMing Fang Hsu
Ming Fang Hsu
YTYen Sheng Tyan
Yen Sheng Tyan
YCYu Chen Chien
Yu Chen Chien
MLMing-Wei Lee
Ming-Wei Lee
The purpose of this study was to develop a gellan gum-based multifunctional embolic agent. Calibrated spherical gellan gum and nanoparticle-containing gellan gum microspheres were prepared via water-in oil emulsification method. Self-assembled nanoparticles composed of short-chain hyaluronic acid and polyethylenimine as the doxorubicin carrier were prepared. The short-chain hyaluronic acid/polyethylenimine/ doxorubicin (sHH/PH/Dox) with the mean size was 140 ± 8 nm. To examine sHH/PH/Dox nanoparticle uptake into cells, the results confirmed that sHH/PH nanoparticles as drug carrier can facilitate the transport of doxorubicin into HepG2 liver cancer cells. Subsequently, sHH/PH/Dox merged into the gellan gum (GG) microspheres forming GG/sHH/PH/Dox microsphere. After a drug release experiment lasting 45 days, the amount of released doxorubicin from 285, 388, and 481 μm GG/sHH/PH/Dox microspheres were approximately 4.8, 1.8 and 1.1-fold above the IC50 value of the HepG2 cell. GG/sHH/PH/Dox microspheres were performed in rabbit ear embolization model and ischemic necrosis on ear was visible due to the vascular after 8 days. Regarding the application of this device in the future, we aim to provide better embolization agents for transcatheter arterial chemoembolization (TACE).

7 March 2013 in Journal of Materials Science: Materials in Medicine
Verified
Journal Article
Closed access
PDF file
HPHsiu-Hui Peng
Hsiu-Hui Peng
YCYi-Min Chen
Yi-Min Chen
CLChen-I Lee
Chen-I Lee
MLMing-Wei Lee
Ming-Wei Lee

3 October 2011 in Journal of Bioactive and Compatible Polymers
Verified
Journal Article
Closed access
HPHsiu-Hui Peng
Hsiu-Hui Peng
JCJia-Wei Chen
Jia-Wei Chen
TYTzi-Peng Yang
Tzi-Peng Yang
CKChung-Fan Kuo
Chung-Fan Kuo
YWYing-Jing Wang
Ying-Jing Wang
MLMing-Wei Lee
Ming-Wei Lee
The purpose of this study was to develop a poly(galacturonic acid) (PGA)-based hydrogel using a short-chain hyaluronate (sHA) cross-linker for medical applications. PGA was grafted with adipic acid dihydrazide (ADH) to yield PGA–ADH, an amine-containing PGA derivative. This PGA–ADH formed a water-insoluble hydrogel by reacting with 1,1′-carbonyldiimidazole (CDI)–grafted sHA (sHA–CDI) in aqueous solution. The sHA–cross-linked PGA hydrogel has a water content of about 94%–97% and compressive modulus of 10.7–26.9 kPa. The in vitro data indicated that the sHA–cross-linked PGA hydrogel is degradable and noncytotoxic, thus suitable for biomedical applications. Animal implant studies showed that the sHA–cross-linked PGA hydrogel membrane exhibited antiadhesion potency, significantly higher than that found in untreated rats and has great potential for future clinical applications.